Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Condition(s):Adenovirus; Primary Immune Deficiency DisorderLast Updated:October 25, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Adenovirus; Primary Immune Deficiency DisorderLast Updated:October 25, 2023Recruiting
Condition(s):Chronic Renal DiseaseLast Updated:April 5, 2018Terminated
Condition(s):Coronavirus Disease 2019Last Updated:January 12, 2024Recruiting
Condition(s):Breast CancerLast Updated:July 24, 2023Recruiting
Condition(s):CMV Viremia; CMV DiseaseLast Updated:April 8, 2019No longer available
Condition(s):Heart DiseasesLast Updated:December 12, 2019Completed
Condition(s):Hematologic MalignancyLast Updated:January 5, 2024Active, not recruiting
Condition(s):Lymphoproliferative DisorderLast Updated:August 6, 2019Completed
Condition(s):Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Lymphoproliferative DisorderLast Updated:December 22, 2017Completed
Condition(s):the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatmentLast Updated:January 6, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.